MCA
BDSX icon

Maryland Capital Advisors’s Biodesix BDSX Stock Holding History

Maryland Capital Advisors’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$626 – 270
2025
Q1 		$626 Buy
+50
New +$960 ﹤0.01% 220

Other funds holding BDSX

TAM
Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Maryland Capital Advisors's BDSX Position: Q2 2025 in Review

Maryland Capital Advisors sold out of Biodesix (BDSX) in Q2 2025, closing a stake of 50 shares — an estimated $626 sold.

Maryland Capital Advisors first reported a position in BDSX in Q1 2025 and held it in 1 quarter. The position peaked at $626 in Q1 2025. 40 funds tracked by Wall St. Rank hold BDSX as of Q2 2025.

  • Maryland Capital Advisors reported no remaining Biodesix position as of Q2 2025 after selling out during the quarter.
  • Maryland Capital Advisors sold 50 Biodesix shares in Q2 2025, an estimated $626.
  • Maryland Capital Advisors first reported a position in Biodesix in Q1 2025 and held it in 1 quarter.
  • Maryland Capital Advisors's Biodesix position peaked at $626 in Q1 2025.
  • 40 funds tracked by Wall St. Rank held Biodesix as of Q2 2025.

Based on Maryland Capital Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.